ES2645095T3 - Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 - Google Patents

Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 Download PDF

Info

Publication number
ES2645095T3
ES2645095T3 ES07812557.2T ES07812557T ES2645095T3 ES 2645095 T3 ES2645095 T3 ES 2645095T3 ES 07812557 T ES07812557 T ES 07812557T ES 2645095 T3 ES2645095 T3 ES 2645095T3
Authority
ES
Spain
Prior art keywords
tau
compound
hsp90
disease
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07812557.2T
Other languages
English (en)
Spanish (es)
Inventor
Gabriela Chiosis
Paul Greengard
Fei Dou
Wenjie Luo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Memorial Sloan Kettering Cancer Center
Original Assignee
Rockefeller University
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, Memorial Sloan Kettering Cancer Center filed Critical Rockefeller University
Application granted granted Critical
Publication of ES2645095T3 publication Critical patent/ES2645095T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES07812557.2T 2006-06-30 2007-07-02 Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 Active ES2645095T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80642706P 2006-06-30 2006-06-30
US806427P 2006-06-30
PCT/US2007/072671 WO2008005937A2 (en) 2006-06-30 2007-07-02 Treatment of neurodegenerative diseases through inhibiton of hsp90

Publications (1)

Publication Number Publication Date
ES2645095T3 true ES2645095T3 (es) 2017-12-04

Family

ID=38895418

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07812557.2T Active ES2645095T3 (es) 2006-06-30 2007-07-02 Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90

Country Status (8)

Country Link
US (5) US10336757B2 (enExample)
EP (2) EP2034839B1 (enExample)
JP (5) JP5599610B2 (enExample)
AU (1) AU2007269144B2 (enExample)
CA (1) CA2656202C (enExample)
DK (1) DK2034839T3 (enExample)
ES (1) ES2645095T3 (enExample)
WO (1) WO2008005937A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084030A2 (en) * 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
NZ572600A (en) * 2006-05-12 2011-08-26 Myrexis Inc 6-Amino-purine derivatives for the treatment of cancer and fibrogenetic disorders
DK2034839T3 (en) * 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Res TREATMENT OF NEURODEGENERATIVE DISEASES BY INHIBITION OF HSP90
NZ579635A (en) 2007-03-20 2011-07-29 Curis Inc Fused amino pyridine as hsp90 inhibitors
NZ586129A (en) * 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
WO2009155936A1 (en) 2008-06-26 2009-12-30 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
AU2013204109B2 (en) * 2009-10-07 2016-05-05 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
KR102129420B1 (ko) 2009-10-07 2020-07-03 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 저해제로서 유용한 퓨린 유도체
JP2013544263A (ja) 2010-11-30 2013-12-12 オルファザイム エーピーエス Ｈｓｐ７０の細胞内活性を上昇させる方法
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
KR101984480B1 (ko) 2011-04-05 2019-05-31 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
EP3208615B1 (en) 2011-07-08 2019-10-09 Sloan Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP2879675B1 (en) 2012-08-06 2019-11-13 Duke University Compounds and methods for targeting hsp90
MA38287B1 (fr) 2013-01-23 2018-08-31 Astrazeneca Ab Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
WO2015023976A2 (en) 2013-08-16 2015-02-19 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof
WO2015038649A1 (en) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
JP6491214B2 (ja) 2013-12-23 2019-03-27 メモリアル スローン ケタリング キャンサー センター 放射性標識のための方法および試薬
WO2015116774A1 (en) 2014-01-29 2015-08-06 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3129064B1 (en) 2014-03-03 2020-01-01 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2015143004A1 (en) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp. Targeted therapeutics
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
JP6835709B2 (ja) * 2014-09-17 2021-02-24 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ９０を標的とした炎症及び感染のイメージング及び療法
TW201722422A (zh) 2015-10-05 2017-07-01 美國紀念斯隆-凱特琳癌症中心 用於治療癌症之合理組合療法
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
CN109069496A (zh) 2016-04-29 2018-12-21 奥菲泽米有限公司 用于治疗葡糖脑苷脂酶相关疾病的arimoclomol
KR102007135B1 (ko) 2017-03-20 2019-08-02 포르마 세라퓨틱스 인크. 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물
EP3615008A4 (en) * 2017-04-24 2021-05-05 Samus Therapeutics, Inc. ORAL HSP90 INHIBITOR FORMULATIONS AND RELATED PROCESSES
CN111511364A (zh) 2017-06-20 2020-08-07 马德里加尔制药公司 靶向治疗剂
WO2018236791A1 (en) 2017-06-20 2018-12-27 Madrigal Pharmaceuticals, Inc. COMBINED THERAPIES COMPRISING TARGETED THERAPEUTICS
US20210161902A1 (en) * 2017-06-23 2021-06-03 Samus Therapeutics, Inc. Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof
IL277071B2 (en) 2018-03-08 2024-07-01 Incyte Corp AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
MX2023005954A (es) 2020-11-19 2023-09-04 Zevra Denmark As Procesos para preparar citrato de arimoclomol e intermediarios del mismo.
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670348B1 (en) 1997-05-14 2003-12-30 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
CA2370007A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
EP1335920B1 (en) * 2000-11-02 2013-04-03 Sloan-Kettering Institute For Cancer Research Compositions containing purine derivatives for binding to hsp90
US20040235813A1 (en) * 2001-05-03 2004-11-25 Erich Wanker Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
AU2002356922A1 (en) 2001-11-09 2003-05-26 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
MXPA04008312A (es) 2002-02-28 2004-11-26 Astrazeneca Ab Derivados de 3-cilil-5-(anillo de 5 miembros que contienen nitrogeno)-metil-oxazolidinona y sus uso como agentes antibacterianos.
EP1620564A4 (en) 2003-04-18 2008-03-12 Cytovia Inc METHODS FOR TREATING DISEASES INDUCING APOPTOSIS INDUCTION AND SCREENING ASSAYS
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
WO2005012482A2 (en) 2003-06-30 2005-02-10 Sloan-Kettering Institute For Cancer Research Assay for identification of bioactive compounds that interact with heat shock protein 90
EP2145888A1 (en) 2003-09-18 2010-01-20 Conforma Therapeutics Corporation Deazapurine derivatives as HSP90-Inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
BRPI0607739A2 (pt) 2005-02-25 2009-09-29 Serenex Inc derivados de tetraidroindolona e tetraidroindazolona, composição compreendendo os mesmos e uso relacionado
WO2006130469A1 (en) * 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
WO2007117466A2 (en) 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
NZ572600A (en) 2006-05-12 2011-08-26 Myrexis Inc 6-Amino-purine derivatives for the treatment of cancer and fibrogenetic disorders
DK2034839T3 (en) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Res TREATMENT OF NEURODEGENERATIVE DISEASES BY INHIBITION OF HSP90
WO2008013985A2 (en) 2006-07-27 2008-01-31 University Of Florida Use of heat shock activators for tissue regeneration
EP2061772A4 (en) 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
US8580519B2 (en) 2006-11-27 2013-11-12 University Of Maryland, Baltimore Use of plasma HSP90 related to malignancy
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
NZ579635A (en) 2007-03-20 2011-07-29 Curis Inc Fused amino pyridine as hsp90 inhibitors
US20100240656A1 (en) 2007-07-12 2010-09-23 Oryzon Genomics, S.A. Compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
NZ586129A (en) 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
KR102129420B1 (ko) 2009-10-07 2020-07-03 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 저해제로서 유용한 퓨린 유도체
KR101984480B1 (ko) 2011-04-05 2019-05-31 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
WO2015023976A2 (en) 2013-08-16 2015-02-19 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof

Also Published As

Publication number Publication date
JP6427227B2 (ja) 2018-11-21
US20140378452A1 (en) 2014-12-25
US10336757B2 (en) 2019-07-02
JP2016028063A (ja) 2016-02-25
JP2009542716A (ja) 2009-12-03
CA2656202C (en) 2018-01-16
WO2008005937A3 (en) 2008-12-11
JP2013177389A (ja) 2013-09-09
JP6585266B2 (ja) 2019-10-02
WO2008005937A2 (en) 2008-01-10
JP5824698B2 (ja) 2015-11-25
US20090298857A1 (en) 2009-12-03
JP5599610B2 (ja) 2014-10-01
EP2034839A2 (en) 2009-03-18
DK2034839T3 (en) 2017-12-04
AU2007269144A1 (en) 2008-01-10
CA2656202A1 (en) 2008-01-10
US12473288B2 (en) 2025-11-18
EP3305297A1 (en) 2018-04-11
AU2007269144B2 (en) 2013-05-16
JP2019038829A (ja) 2019-03-14
EP2034839B1 (en) 2017-08-23
EP2034839A4 (en) 2012-08-29
US20240158397A1 (en) 2024-05-16
US20190389864A1 (en) 2019-12-26
US20230060990A1 (en) 2023-03-02
JP2017214379A (ja) 2017-12-07

Similar Documents

Publication Publication Date Title
ES2645095T3 (es) Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
Mazanetz et al. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Šála et al. Novel human neutral sphingomyelinase 2 inhibitors as potential therapeutics for Alzheimer’s disease
ES2213996T3 (es) Uso de himenialdisina o sus derivados en la fabricacion de medicamentos.
Hirai et al. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases
US20220313628A1 (en) Methods for selecting phosphatase selective and non-selective phosphatase inhibitors
US20100247517A1 (en) Use of mnk inhibitors for the treatment of alzheimer's disease
EP1686988A1 (en) Indirubin-type compounds, compositions, and methods for their use
US8357673B2 (en) 4-arylazo-3,5-diamino-pyrazole compounds and use thereof
Liu et al. Development of bisindole-substituted aminopyrazoles as novel GSK-3β inhibitors with suppressive effects against microglial inflammation and oxidative neurotoxicity
AU2017200078B2 (en) Treatment of neurodegenerative diseases through inhibition of Hsp90
HK1253803A1 (en) Treatment of neurodegenerative diseases through inhibition of hsp90
Yang et al. Alzheimer's Disease and Cancer: Common Targets
Kehoe et al. P3-242 Induction of the heat shock response protects against tau associated toxicity in M17 cell lines